CN102727706A - Composition for preventing and treating diabetes - Google Patents
Composition for preventing and treating diabetes Download PDFInfo
- Publication number
- CN102727706A CN102727706A CN2011100840922A CN201110084092A CN102727706A CN 102727706 A CN102727706 A CN 102727706A CN 2011100840922 A CN2011100840922 A CN 2011100840922A CN 201110084092 A CN201110084092 A CN 201110084092A CN 102727706 A CN102727706 A CN 102727706A
- Authority
- CN
- China
- Prior art keywords
- diabetes
- weight portion
- preferably contains
- compositions
- poria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a composition for preventing and treating diabetes, which comprises the following ingredients by weight: 1-100 parts of cinnamon, 1-100 parts of mulberry leaf, 1-100 parts of root of kudzu vine, 1-100 parts of Poria cocos, 1-100 parts of Chinese yam and 1-100 parts of bitter gourd. The composition possesses good hypoglycemic effect, and is especially suitable for preventing and treating of spleen and kidney insufficiency type diabetes.
Description
Technical field
The present invention relates to prevent and treat the compositions of diabetes.Being specifically related to Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria, Rhizoma Dioscoreae and Fructus Momordicae charantiae is the prevention of primary raw material preparation and the compositions of treatment diabetes.
Background technology
Present global diabetics is 2.85 hundred million, and China's diabetics is about 9,240 ten thousand, and the prediabetes patient 1.48 hundred million, and diabetes have become the fourth-largest disease that causes global human mortality.In view of the significant damage that diabetes are brought to the mankind, World Health Organization (WHO) is referred to as " disaster of 21 century ".The course of disease of diabetes is long, and medical expense is expensive, and according to diabetology branch of Chinese Medical Association statistics, the direct medical expenses of Chinese diabetes reaches 1,734 hundred million yuan, accounts for 13% of national medical total expenses.Not only influenced patient's life and quality of life, also brought heavy financial burden, therefore developed health food or food and have economical, societal benefits widely with auxiliary hyperglycemic function to the country and people.
Mainly adopt such as chemicalses such as biguanide drug, sulfonylurea medicine, insulins for the prevention and the treatment of diabetes at present both at home and abroad, but there is following problem in these medicines: the biguanides curative effect is low, and side effect is big, for a long time with producing hyperlactacidemia; Sulfonylureas is for a long time with infringement liver, kidney, with sulfa drugs generation cross allergy; With producing antibody, biological activity reduces insulin for a long time, and dosage increases, and produces hyperinsulinemia.
In recent years, along with the research of relevant natural plants hypoglycemic activity deepens continuously, with natural plants or its activity extract be that the feedstock production side effect is less, the research of the medicine that is suitable for long-term prevention and treatment diabetes and health product is increasing.With natural plants or its activity extract is a new direction of medicine and health product research becoming gradually exploitation prevention and the treatment diabetes medicament and the health product of raw material.
One Chinese patent application 01120226.2 discloses a kind of prescription and preparation process of health food of blood sugar regulation; It is to be raw material with Folium Mori and Fructus Momordicae charantiae, according to the special method for distilling of the characteristics design of every flavor Chinese medicine and adopt the sugar-free adjuvant that it is mixed with the teabag dosage form.This health food is oral obviously to reduce alloxan diabetes mice post-prandial glycemia; Increase the carbohydrate tolerance of diabetic mice; Do not increase the insulin level of normal mouse; Through clinical trial, these article can obviously reduce the rising of type ii diabetes people post-prandial glycemia, are that a kind of effective blood sugar regulation also can supply the long-term oral health food of patient.
One Chinese patent application 200710177487.0 discloses a kind of Chinese medicine composition with function of blood sugar reduction and preparation method thereof.This Chinese medicine composition is to be prepared from according to a certain weight ratio Fructus Momordicae charantiae, Semen Fagopyri Esculenti, Folium Mori and propolis.It can be prepared to any dosage form for oral administration commonly used.Chinese medicine composition of the present invention has effect in reducing blood glucose, can be used for treating diabetes.
One Chinese patent application 200710178507.6 discloses a kind of Chinese medicine composition with function of blood sugar reduction and preparation method thereof.This Chinese medicine composition is to be prepared from according to a certain weight ratio Fructus Momordicae charantiae, Folium Mori and Rhizoma Polygonati Odorati.It can be prepared to any dosage form for oral administration commonly used.Chinese medicine composition of the present invention has effect in reducing blood glucose, can be used for treating diabetes.
Above-mentioned patent application does not all relate to yang deficiency of spleen and stomache treatment of diabetes and prevention.
Diabetes belong to the diabetes scope in the traditional Chinese medical science, at present the traditional Chinese medical science with diabetes be divided into roughly that the deficiency of YIN is scorching, deficiency of both QI and YIN, deficiency of both YIN and YANG.Diabetes is treated in warming YANG ruling by law, initiates in Zhang Zhongjing.Back physicians from a family for generations' daily life of a family is used for the deficiency of both YIN and YANG stage in diabetes later stage to this method.But deepen continuously along with what diabetes was familiar with, reach the progress to its prevention and treatment of complication, finding quenches one's thirst also has factor body yang deficiency, and from the beginning of promptly having the deficiency of vital energy and yang deficiency person simultaneously concurrently, spleen kidney yang QI-insufficiency is the pathogenesis essence of type 2 diabetes mellitus insulin resistant.Spleen kidney yang QI-insufficiency causes the yang deficiency of spleen and stomache diabetes, and its classical symptom comprises that coldness of the body with chills, spiritlessness and weakness, soreness of the waist and knees, limbs edema, numb pain, complexion white, clear urine in large amounts or deficient, nocturia increase, defecate uncomfortable etc.Therefore, treat and prevent the medicine of yang deficiency of spleen and stomache diabetes and health product to exist demand for being used to.
Summary of the invention
The object of the present invention is to provide a kind of hypoglycemic activity that has, be intended to prevent and treat the compositions of diabetes.The various symptoms that said composition can be used for reducing the sickness rate of diabetes and effectively alleviates diabetes are particularly effective to the control of yang deficiency of spleen and stomache diabetes.
For realizing above-mentioned purpose; The inventor is based on understanding and the Therapeutic Principle of the traditional Chinese medical science for diabetes and complication mechanism thereof; In conjunction with pharmacological research, animal experiment and clinical trial to medicinal plants; Through deeply screening for many years, select to contain Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria, Rhizoma Dioscoreae and the Fructus Momordicae charantiae of certain content the present composition as essential component.
As the primary raw material of the preparation present composition, Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria, Rhizoma Dioscoreae and Fructus Momordicae charantiae have following effect:
1. Cortex Cinnamomi
Cortex Cinnamomi is the cinnamomic dry bark of canella, and record the earliest comes from Shennong's Herbal, is clinical drugs for dispelling internal cold commonly used.It is fiery supporing yang that Cortex Cinnamomi has benefit, let the fire back to its origin, dispersing cold for relieving pain, the function of promoting blood circulation to restore menstrual flow.The Cortex Cinnamomi ingredient has volatile oil (cinnamic aldehyde), tannin, sesquiterpene, diterpene-kind compound etc.Discover much that in recent years Cortex Cinnamomi has blood sugar lowering and effect for reducing blood fat.The hypoglycemic mechanism of action of Cortex Cinnamomi comprises: the content that 1. increases serum insulin through protection, stimulation beta Cell of islet; 2. increase the sensitivity of insulin, improve insulin resistant; 3. remove free radical, anti peroxidation of lipid; 4. promote insulin secretion, increase the content of serum insulin.
2. Folium Mori
Folium Mori have the effect of expelling wind and clearing away heat, cooling blood for improving eyesight.Modern study shows: alkaloid 1-deoxynojirimycin (DNJ) in the Folium Mori (content is 0.1～0.3%) is topmost blood sugar lowering effective ingredient.DNJ is effective inhibitor of mammal alpha-glucosidase activity; Alpha-glucosidase main being responsible in human body downcut glucose from the non-reducing end of starch and relevant polysaccharide, therefore, and after alpha-glucosidase activity is suppressed; Thereby slow down the formation speed of intestinal glucose; Reduced the regular supply of glucose to little intestinal absorption, delay with blood sugar lowering in the phenomenon that raises fast after the meal, reach the purpose of treatment and control of diabetes.The main component of the medicine " acarbose " of the treatment diabetes that Germany produces is exactly an alpha-glucosidase activity inhibitor.
3. Radix Puerariae
Radix Puerariae sweet in the mouth, cool in nature is returned taste, and the merit of promoting the production of body fluid to quench thirst is arranged, and is the medicine commonly used that treatment is quenched one's thirst.Research shows that the osajin composition puerarin of Radix Puerariae can promote β emiocytosis insulin, strengthens the sensitivity of histiocyte to insulin, thus blood sugar lowering.
4. Poria
Poria is a kind of strain that parasitizes on the Pinaceae tree planting root, and the Poria of genus polyporus Cordycepps belongs to.In the Compendium of Material Medica of Ming Dynasty's Li Shizhen (1518-1593 A.D.) and ancient medical book " not Lu ", " moral is given birth to hall through proved recipe ", all put down in writing Poria the effect of only quenching one's thirst is arranged.93% of Poria dry weight is β-pachyman, and β-pachyman is a kind of dietary fiber, but is insoluble dietary fiber mostly.Research shows that edible Poria has certain blood sugar lowering and reduces the effect of body constitution amount the type ii diabetes patient.
5. Rhizoma Dioscoreae
The Rhizoma Dioscoreae supplementing QI and nourishing YIN, property is flat and not dry, with the existing long history of its treatment diabetes.Many Chinese patent medicine name sides like LIUWEI DIHUANG WAN, good wine soup etc., all are furnished with Rhizoma Dioscoreae.Research in recent years shows that list uses heavy dose of Rhizoma Dioscoreae to be staple food, and decocting in water connects soup to be taken, and the treatment diabetes are effective, verified the science reason in the conventional formulation.Research in recent years shows; Rhizoma Dioscoreae can obviously reduce blood glucose in diabetic rats; Improve the anti-sugar amount of rat, the also corresponding rising of C peptide value simultaneously, prove thus Chinese yam polysaccharide to the treatment of diabetes effect maybe with increase insulin secretion, to improve impaired beta Cell of islet function relevant.
6. Fructus Momordicae charantiae
China just is used as medicinal plants utilization to Fructus Momordicae charantiae since ancient times.In ancient Chinese proses such as herbal for Relief of Famines and Compendium of Material Medica are offered, all once mentioned Fructus Momordicae charantiae.Aspect diabetes, stress all that it can " quench the thirst ", " curing mainly the excessive thirst taking fluids profusely " etc.The Ming Dynasty's big medicine scholar Li Shizhen (1518-1593 A.D.) is said: " the Fructus Momordicae charantiae nature and flavor are bitter, cold, nontoxic, have except that pathogenic heat, separate tired, clear away heart-fire make eye bright, the effect of QI invigorating tonifying YANG." Fructus Momordicae charantiae is very effective in cure for the retinopathy of one of diabetes three big complication.
The present invention provides following technical scheme:
1, compositions, in weight portion, it contains Cortex Cinnamomi 1-100, Poria 1-100, Rhizoma Dioscoreae 1-100, Folium Mori 1-100, Radix Puerariae 1-100, Fructus Momordicae charantiae 1-100.
2, according to the compositions of technical scheme 1, in weight portion, it contains Cortex Cinnamomi 10-60, preferably contains Cortex Cinnamomi 20-40, more preferably contains Cortex Cinnamomi 30-35.
3, according to each compositions in the aforementioned techniques scheme, in weight portion, it contains Poria 5-50, preferably contains Poria 15-30, more preferably contains Poria 20-25.
4, according to each compositions in the aforementioned techniques scheme, in weight portion, it contains Rhizoma Dioscoreae 5-40, preferably contains Rhizoma Dioscoreae 10-25, more preferably contains Rhizoma Dioscoreae 15-20.
5, according to each compositions in the aforementioned techniques scheme, in weight portion, it contains Folium Mori 1-30, preferably contains Folium Mori 5-20, more preferably contains Folium Mori 5-15.
6, according to each compositions in the aforementioned techniques scheme, in weight portion, it contains Radix Puerariae 1-30, preferably contains Radix Puerariae 5-20, more preferably contains Radix Puerariae 5-15.
7, according to each compositions in the aforementioned techniques scheme, in weight portion, it contains Fructus Momordicae charantiae 1-30, preferably contains Fructus Momordicae charantiae 5-20, more preferably contains Fructus Momordicae charantiae 5-15.
8, product, it comprises each described compositions among the technical scheme 1-7, and said product is medicine or health product.
9, each described compositions is used for treatment or prevent diabetes in preparation among the technical scheme 1-7, the medicine of preferred yang deficiency of spleen and stomache diabetes or the purposes in the health product.
10, according to technical scheme 8 described products, it is a granule, tablet, capsule, oral liquid, solid beverage, teabag or powder.
The specific embodiment
In the present composition, primary raw material Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria, Rhizoma Dioscoreae and Fructus Momordicae charantiae complement each other, and have collaborative hypoglycemic activity, especially are fit to prevention and treatment yang deficiency of spleen and stomache diabetes.
In weight portion, the present composition contains Cortex Cinnamomi 1-100, Poria 1-100, Rhizoma Dioscoreae 1-100, Folium Mori 1-100, Radix Puerariae 1-100, Fructus Momordicae charantiae 1-100.In said composition, cinnamomic content is preferably the 10-60 weight portion, more preferably 20-40 weight portion, more preferably 30-35 weight portion; The content of Poria is preferably the 5-50 weight portion, more preferably 15-30 weight portion, more preferably 20-25 weight portion; The content of Rhizoma Dioscoreae is preferably the 5-40 weight portion, more preferably 10-25 weight portion, more preferably 15-20 weight portion; The content of Folium Mori is preferably the 1-30 weight portion, more preferably 5-20 weight portion, more preferably 5-15 weight portion; The content of Radix Puerariae is preferably the 1-30 weight portion, more preferably 5-20 weight portion, more preferably 5-15 weight portion; The content of Fructus Momordicae charantiae is preferably the 1-30 weight portion, more preferably 5-20 weight portion, more preferably 5-15 weight portion.
In a kind of preferred implementation, in weight portion, the present composition contains Cortex Cinnamomi 10-60, Poria 5-50, Rhizoma Dioscoreae 5-40, Folium Mori 1-30, Radix Puerariae 1-30, Fructus Momordicae charantiae 1-30.In the another kind of preferred implementation, in weight portion, the present composition contains Cortex Cinnamomi 20-40, Poria 15-30, Rhizoma Dioscoreae 10-25, Folium Mori 5-20, Radix Puerariae 5-20, Fructus Momordicae charantiae 5-20.In another preferred implementation, in weight portion, the present composition contains Cortex Cinnamomi 30-35, Poria 20-25, Rhizoma Dioscoreae 15-20, Folium Mori 5-15, Radix Puerariae 5-15, Fructus Momordicae charantiae 5-15.
In above-mentioned composition; Raw material Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria, Rhizoma Dioscoreae and Fructus Momordicae charantiae can adopt former powder; Former powder can adopt the commercially available prod, and perhaps conventional pulverizing, the technology of sieving of utilization handled commercially available Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria, Rhizoma Dioscoreae and Fructus Momordicae charantiae and prepared.Wherein Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria and Rhizoma Dioscoreae should meet the corresponding requirements of one one of the Pharmacopoeia of the People's Republic of China (2010 editions), and the content of total Saponin should be not less than about 0.01% of Fructus Momordicae charantiae powder gross weight in the Fructus Momordicae charantiae powder.In one embodiment, Fructus Momordicae charantiae powder is generally the pistac uniform powder, has distinctive flavour of Fructus Momordicae charantiae and fragrance, preferred mistake 80 mesh sieves.
Can further add acceptable auxiliary additive on pharmaceutically acceptable auxiliary additive or the food at the present composition, thereby process the product that is used to prevent and treat diabetes, this product can be medicine or health product etc.As required, can said product be processed forms such as granule, tablet, capsule, oral liquid, solid beverage, teabag, powder.
Be applicable to that acceptable auxiliary additive includes but not limited to binding agent, lubricant, disintegrating agent, correctives, antioxidant etc. on pharmaceutically acceptable auxiliary additive or the food in the present composition.
Above-mentioned binding agent includes but not limited to hydroxypropyl cellulose, corn starch, pregelatinized Starch, modified corn starch, polyvinylpyrrolidone, hydroxypropyl emthylcellulose, lactose, arabic gum, ethyl cellulose, cellulose acetate etc.
Above-mentioned lubricant includes but not limited to magnesium stearate, zinc stearate, calcium stearate, Talcum, stearic acid, silica sol, Palmic acid etc.
Above-mentioned disintegrating agent includes but not limited to cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, starch, potato starch, pregelatinized Starch, corn starch, primojel, microcrystalline Cellulose, hydroxypropyl cellulose etc.
Above-mentioned correctives includes but not limited to fruit essence, aspartame, stevioside etc.
Above-mentioned antioxidant includes but not limited to anti-butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG), ascorbic acid, alpha-tocopherol etc.
In a kind of embodiment, can the present composition be processed tablet through following method:
With Cortex Cinnamomi, Folium Mori, Radix Puerariae, Rhizoma Dioscoreae, Poria, Fructus Momordicae charantiae pulverize separately, cross 100 mesh sieves.With above-mentioned medicated powder and auxiliary additive (for example microcrystalline Cellulose, hydroxypropyl emthylcellulose, polyvinylpyrrolidone, carboxymethyl starch are received) mix homogeneously, make soft material in right amount with 50% ethanol, 20 mesh sieves are granulated; 60 ℃ of dryings; 20 mesh sieve granulate add the magnesium stearate mix homogeneously, and tabletting promptly gets.
Beneficial effect
The present composition that contains Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria, Rhizoma Dioscoreae and Fructus Momordicae charantiae after deliberation compares with model group, and the OLETF rat is had significant blood sugar decreasing effect, with positive control rosiglitazone suitable (seeing embodiment 3).
Through 30 routine clinical observations, diabetics is taken the present composition, each 2g, every day 3 times, logotype 30 days.The result: produce effects 22 examples, effective 6 examples, total effective rate is 93.3%, an invalid example.To coldness of the body with chills, spiritlessness and weakness, soreness of the waist and knees, limbs edema, numb pain, complexion white, clear urine in large amounts or deficient, the nocturia symptom such as uncomfortable that increases, defecates, taking just had positive effect (seeing embodiment 4) in 15 days.
Present composition side effect is little, safe in utilization.The ICR acute toxicity test in mice shows: with 80 times of gastric infusions of clinical dosage (2 grams/inferior, 3 times/day), observed none death continuously 7 days.Long term toxicity test shows with 40 times of clinical dosage gives SD rat continuous irrigation stomach, observes not occur obvious toxic and side effects in 6 months.
The present composition can be prepared into health product, edible safety, health invigorating, effectively prevent diabetes, the especially generation of yang deficiency of spleen and stomache diabetes.
Embodiment
Below through embodiment the present invention is illustrated, following examples limit the invention never in any form.
In following examples, all raw materials and reagent adopt the commercially available prod, and wherein Cortex Cinnamomi is available from hundred primary Chinese herbal medicine company limiteies of Guangxi Yulin; Radix Puerariae, Folium Mori, Rhizoma Dioscoreae and Poria are available from Suzhou light of spring hall pharmaceutcal corporation, Ltd; Fructus Momordicae charantiae is available from Ou Shang Suzhou golden pheasant Hu Dian.
Embodiment 1: the present composition product that contains Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria, Rhizoma Dioscoreae and Fructus Momordicae charantiae
| Dosage form | Capsule (mg) | Tablet (mg) | Solid beverage (mg) | Teabag (mg) |
| Cortex Cinnamomi | 200 | 110 | 1000 | 1000 |
| Poria | 80 | 110 | 1200 | 1000 |
| Rhizoma Dioscoreae | 60 | 60 | 800 | 1000 |
| Folium Mori | 40 | 30 | 400 | 1000 |
| Radix Puerariae | 40 | 20 | 400 | 500 |
| Fructus Momordicae charantiae | 30 | 20 | 200 | 500 |
| Microcrystalline Cellulose | --- | 64 | --- | --- |
| Hydroxypropyl emthylcellulose | --- | 50 | --- | --- |
| Polyvinylpyrrolidone k30 | --- | 25 | --- | --- |
| Carboxymethyl starch sodium | --- | 10 | --- | --- |
| Magnesium stearate | --- | 1 | --- | --- |
| Maltodextrin | --- | --- | 500 | --- |
| Stevioside | --- | --- | 500 | --- |
| Product specification | The 450mg/ grain | The 500mg/ sheet | The 5000mg/ bag | The 5000mg/ bag |
Capsule preparation method thereof: Cortex Cinnamomi, Folium Mori, Radix Puerariae, Rhizoma Dioscoreae, Poria, Fructus Momordicae charantiae are pulverized, crossed 80 mesh sieves, take by weighing each batching according to prescription, mix homogeneously incapsulates, and promptly gets.
Method for preparing tablet thereof:, cross 100 mesh sieves with Cortex Cinnamomi, Folium Mori, Radix Puerariae, Rhizoma Dioscoreae, Poria, Fructus Momordicae charantiae pulverize separately.Take by weighing each batching according to prescription; With above-mentioned medicated powder and microcrystalline Cellulose, hydroxypropyl emthylcellulose, polyvinylpyrrolidone K30, carboxymethyl starch receive, mix homogeneously, make soft material in right amount with 50% ethanol, 20 mesh sieves are granulated; 60 ℃ of dryings; 20 mesh sieve granulate add the magnesium stearate mix homogeneously, and tabletting promptly gets.
Method for preparing solid beverage thereof:, cross 60 mesh sieves with Cortex Cinnamomi, Folium Mori, Radix Puerariae, Rhizoma Dioscoreae, Poria, Fructus Momordicae charantiae pulverize separately.Take by weighing each batching according to prescription, with above-mentioned medicated powder and maltodextrin, stevioside mix homogeneously, packing promptly gets.
Preparation method of teabag: Cortex Cinnamomi, Folium Mori, Radix Puerariae, Rhizoma Dioscoreae, Poria, Fructus Momordicae charantiae are pulverized, crossed the 20-30 mesh sieve, take by weighing each batching according to prescription, mix homogeneously, packing promptly gets.
Embodiment 2: the present composition product that contains Cortex Cinnamomi, Folium Mori, Radix Puerariae, Poria, Rhizoma Dioscoreae and Fructus Momordicae charantiae
| Dosage form | Capsule (mg) | Tablet (mg) | Solid beverage (mg) | Teabag (mg) |
| Cortex Cinnamomi | 270 | 35 | 80 | 75 |
| Poria | 90 | 175 | 20 | 50 |
| Rhizoma Dioscoreae | 76.5 | 17.5 | 160 | 50 |
| Folium Mori | 4.5 | 52.5 | 120 | 25 |
| Radix Puerariae | 4.5 | 35 | 4 | 150 |
| Fructus Momordicae charantiae | 4.5 | 35 | 16 | 150 |
| Microcrystalline Cellulose | --- | 64 | --- | --- |
| Hydroxypropyl emthylcellulose | --- | 50 | --- | --- |
| Polyvinylpyrrolidone k30 | --- | 25 | --- | --- |
| Carboxymethyl starch sodium | --- | 10 | --- | --- |
| Magnesium stearate | --- | 1 | --- | --- |
| Maltodextrin | --- | --- | 500 | --- |
| Stevioside | --- | --- | 500 | --- |
| Product specification | The 450mg/ grain | The 500mg/ sheet | The 5000mg/ bag | The 5000mg/ bag |
Method for preparing is with embodiment 1.
The hypoglycemic activity of 3 pairs of OLETF rats of embodiment
Sample is selected the capsule 's content among the embodiment 1 for use.
40 OLETF rats (available from Japan's big tomb pharmacy Tokushima institute, 20 ages in week, male and female half and half) are raised under no-special pathogen level (SPF level) condition, raised with standard feed (available from west, Shanghai pul-Bi Kai laboratory animal company limited).In raising to 32 week, be divided into 4 groups at random.In 4 weeks of gastric infusion, once a day, dosage is 1. model group: normal saline, 3mL/ are only; 2. Western medicine group: rosiglitazone, 1.5mg/kg body weight; 3. Chinese medicine small dose group: present composition 0.6g/kg body weight; 4. Chinese medicine is heavy dose of organizes: present composition 1.2g/kg body weight.Administration finishes the fasting glucose that each group is detected in the back.
Table 1 is respectively organized fasting glucose relatively
Compare with model group,
*P＜0.05
Visible from table 1, compare with the model group fasting glucose, Western medicine rosiglitazone group, the heavy dose of group of Chinese medicine be blood sugar lowering (p＜0.05) significantly.
The experiment of embodiment 4 effect of lowering blood sugar
(1) clinical data 60 routine deficiency of spleen-YANG and kidneyYANG diabetes mellitus types are divided into two groups at random, and 30 examples are organized in treatment, wherein male 15 examples, women 15 examples, 64 years old ± 8.2 years old age, the course of disease 7.53 ± 5.48 years; Matched group 30 examples, wherein male 15 examples, women 15 examples, 65 years old ± 8.9 years old age, the course of disease 7.37 ± 5.37.Through statistical procedures, the equal not statistically significant of each item index difference has comparability between two groups.
(2) tablet in the oral embodiment of the invention 1 is organized in the Therapeutic Method treatment, and every day 3 times, each 4, be 30 days the course of treatment.Matched group gives SHENQI JIANGTANG KELI 3 grams, and every day 3 times, be 30 days the course of treatment.
(3) observation index
1. curative effect index
Fasting glucose, 2 hours after the meal blood glucose, glycolated hemoglobin are all respectively surveyed 1 time before treatment and during the treatment end.
2. tcm symptom
Observe following symptom variation: coldness of the body with chills, spiritlessness and weakness, soreness of the waist and knees, limbs edema, numb pain, complexion white, clear urine in large amounts or deficient, nocturia increase, defecate uncomfortable.With above-mentioned symptom basis " the clinical research guidelines of new Chinese medicine treatment diabetes " (2002 editions) " tcm symptom scalar quantization standard "; Be divided into nothing, light, in, weigh four grades; Adopt sxemiquantitative grade score evaluation methodology; Count 0,2,4,6 fen, respectively at before the treatment, the registration of scoring after the treatment, observe integration variation before and after the treatment.
(4) criterion of therapeutical effect is worked out with reference to the clinical research guideline of the treatment of the new Chinese medicine in new Chinese medicine clinical research guideline diabetes.
1. produce effects: fasting glucose and 2 hours after the meal blood glucose drop to normal range; Or fasting glucose and 2 hours after the meal blood glucose values descend and surpass 40% before the treatment, and the glycolated hemoglobin value drops to normally, or descend surpass treatment preceding 30%.
2. effective: fasting glucose and 2 hours after the meal blood glucose descend and surpass 20% before the treatment, but do not reach the produce effects standard, and the glycolated hemoglobin value descends and surpasses 10% before the treatment, but does not reach the produce effects standard.
3. tcm symptom does not all have obvious improvement, even increase the weight of, the disease integration reduces less than 30%; Fasting glucose and 2 hours after the meal blood glucose do not have decline, or descend and do not reach effective standard, and the glycolated hemoglobin value does not have decline, or descend and do not reach effective standard.
(5) the efficacy result treatment is organized in 30 examples, produce effects 22 examples, effective 6 examples, invalid 2 examples, total effective rate 93.3%, matched group 30 examples, produce effects 17 examples, effective 5 examples, invalid 7 examples, total effective rate 73.3%.
(6) two groups of patient of therapeutic evaluation are after 30 days, and there were significant differences aspect curative effect (P＜0.05), improves the aspect analysis from leading indicators such as patient's blood glucose, tcm symptoms, and the treatment group has better action, and the result sees table 2 and table 3.
Fasting glucose, 2h blood glucose, glycolated hemoglobin comparison after the meal before and after the table 2 liang group patient
It is relatively preceding with treatment,
*P＜0.01
The tcm symptom integration relatively before and after the table 3 liang group patient
It is relatively preceding with treatment,
*P＜0.05,
*P＜0.01
Comprehensive clinical observation result can draw to draw a conclusion:
1. invent related prevention and the treatment diabetes especially the compositions of yang deficiency of spleen and stomache diabetes have good blood sugar reducing function, no matter be fasting glucose or 2 hours after the meal blood glucose, all have clear improvement.
2. the compositions of inventing related prevention and treatment diabetes has significant improvement effect for the coldness of the body with chills of yang deficiency of spleen and stomache diabetes, spiritlessness and weakness, soreness of the waist and knees, limbs edema, numb pain, complexion white, clear urine in large amounts or deficient, the nocturia clinical symptoms such as uncomfortable that increases, defecates.
The description of the above-described embodiment and examples of the present invention from explaination and illustrative purposes, is not to limit the present invention by any way only.Clearly, those skilled in the art according to the present invention contextual instruction can carry out multiple change and variation.These changes and changing in the spirit and scope of the invention all drop on claim and limited.
Claims (10)
1. compositions, in weight portion, it contains Cortex Cinnamomi 1-100, Poria 1-100, Rhizoma Dioscoreae 1-100, Folium Mori 1-100, Radix Puerariae 1-100, Fructus Momordicae charantiae 1-100.
2. according to the compositions of claim 1, in weight portion, it contains Cortex Cinnamomi 10-60, preferably contains Cortex Cinnamomi 20-40, more preferably contains Cortex Cinnamomi 30-35.
3. according to each compositions in the aforementioned claim, in weight portion, it contains Poria 5-50, preferably contains Poria 15-30, more preferably contains Poria 20-25.
4. according to each compositions in the aforementioned claim, in weight portion, it contains Rhizoma Dioscoreae 5-40, preferably contains Rhizoma Dioscoreae 10-25, more preferably contains Rhizoma Dioscoreae 15-20.
5. according to each compositions in the aforementioned claim, in weight portion, it contains Folium Mori 1-30, preferably contains Folium Mori 5-20, more preferably contains Folium Mori 5-15.
6. according to each compositions in the aforementioned claim, in weight portion, it contains Radix Puerariae 1-30, preferably contains Radix Puerariae 5-20, more preferably contains Radix Puerariae 5-15.
7. according to each compositions in the aforementioned claim, in weight portion, it contains Fructus Momordicae charantiae 1-30, preferably contains Fructus Momordicae charantiae 5-20, more preferably contains Fructus Momordicae charantiae 5-15.
8. product, it comprises each described compositions among the claim 1-7, and said product is medicine or health product.
9. each described compositions is used for treatment or prevent diabetes in preparation among the claim 1-7, the medicine of preferred yang deficiency of spleen and stomache diabetes or the purposes in the health product.
10. product according to claim 8, it is a granule, tablet, capsule, oral liquid, solid beverage, teabag or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100840922A CN102727706A (en) | 2011-04-02 | 2011-04-02 | Composition for preventing and treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100840922A CN102727706A (en) | 2011-04-02 | 2011-04-02 | Composition for preventing and treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102727706A true CN102727706A (en) | 2012-10-17 |
Family
ID=46984470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100840922A Pending CN102727706A (en) | 2011-04-02 | 2011-04-02 | Composition for preventing and treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727706A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104082742A (en) * | 2014-07-04 | 2014-10-08 | 凯泽（武汉）健康管理有限公司 | Functional food for adjusting blood glucose balance |
| CN104256782A (en) * | 2014-09-23 | 2015-01-07 | 孟州世博生物科技有限公司 | Radix puerariae and Chinese yam beverage and preparation method thereof |
| CN105360455A (en) * | 2014-08-18 | 2016-03-02 | 周峰 | Kudzuvine root-barbary wolfberry fruit tea and preparing method thereof |
| CN106074971A (en) * | 2016-07-13 | 2016-11-09 | 湖北中医药大学 | A kind of hypoglycemic traditional Chinese medicine composition and preparation method and application |
| CN106262841A (en) * | 2016-08-05 | 2017-01-04 | 张德怀 | A kind of for preventing and the nutritive powder treating diabetes and preparation method thereof |
| CN110839805A (en) * | 2019-11-22 | 2020-02-28 | 坤承(北京)健康管理有限公司 | Plant solid beverage |
| CN113648380A (en) * | 2021-09-03 | 2021-11-16 | 杨长俊 | Composition for treating diabetes |
| CN114098072A (en) * | 2021-10-22 | 2022-03-01 | 长沙四气扁鹊堂健康管理有限公司 | Medicinal and edible material composition and extract for assisting in regulating blood sugar, and preparation method and application thereof |
| CN115364170A (en) * | 2022-10-20 | 2022-11-22 | 云南中医药大学 | Sugar metabolism regulator and preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364610A (en) * | 2001-03-20 | 2002-08-21 | 薛志祥 | Blood sugar reducing tea |
| CN1813910A (en) * | 2005-02-05 | 2006-08-09 | 北京北大维信生物科技有限公司 | Medicinal composition with blood sugar reducing action and its preparing method |
| CN101028410A (en) * | 2007-04-16 | 2007-09-05 | 北京艺信堂医药研究所 | Hypoglycemic health-care product |
| CN101269162A (en) * | 2008-05-12 | 2008-09-24 | 北京星昊医药股份有限公司 | Combination for auxiliary treatment of diabetes |
| CN101455379A (en) * | 2008-11-27 | 2009-06-17 | 成都润馨堂药业有限公司 | Nutrient food suitable of diabetic and preparation method thereof |
| CN101695376A (en) * | 2009-10-14 | 2010-04-21 | 寇开勤 | Health-care food for preventing diabetes |
-
2011
- 2011-04-02 CN CN2011100840922A patent/CN102727706A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364610A (en) * | 2001-03-20 | 2002-08-21 | 薛志祥 | Blood sugar reducing tea |
| CN1813910A (en) * | 2005-02-05 | 2006-08-09 | 北京北大维信生物科技有限公司 | Medicinal composition with blood sugar reducing action and its preparing method |
| CN101028410A (en) * | 2007-04-16 | 2007-09-05 | 北京艺信堂医药研究所 | Hypoglycemic health-care product |
| CN101269162A (en) * | 2008-05-12 | 2008-09-24 | 北京星昊医药股份有限公司 | Combination for auxiliary treatment of diabetes |
| CN101455379A (en) * | 2008-11-27 | 2009-06-17 | 成都润馨堂药业有限公司 | Nutrient food suitable of diabetic and preparation method thereof |
| CN101695376A (en) * | 2009-10-14 | 2010-04-21 | 寇开勤 | Health-care food for preventing diabetes |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104082742A (en) * | 2014-07-04 | 2014-10-08 | 凯泽（武汉）健康管理有限公司 | Functional food for adjusting blood glucose balance |
| CN105360455A (en) * | 2014-08-18 | 2016-03-02 | 周峰 | Kudzuvine root-barbary wolfberry fruit tea and preparing method thereof |
| CN104256782A (en) * | 2014-09-23 | 2015-01-07 | 孟州世博生物科技有限公司 | Radix puerariae and Chinese yam beverage and preparation method thereof |
| CN106074971A (en) * | 2016-07-13 | 2016-11-09 | 湖北中医药大学 | A kind of hypoglycemic traditional Chinese medicine composition and preparation method and application |
| CN106074971B (en) * | 2016-07-13 | 2020-04-17 | 湖北中医药大学 | Traditional Chinese medicine composition for reducing blood sugar, preparation method and application |
| CN106262841A (en) * | 2016-08-05 | 2017-01-04 | 张德怀 | A kind of for preventing and the nutritive powder treating diabetes and preparation method thereof |
| CN110839805A (en) * | 2019-11-22 | 2020-02-28 | 坤承(北京)健康管理有限公司 | Plant solid beverage |
| CN113648380A (en) * | 2021-09-03 | 2021-11-16 | 杨长俊 | Composition for treating diabetes |
| CN114098072A (en) * | 2021-10-22 | 2022-03-01 | 长沙四气扁鹊堂健康管理有限公司 | Medicinal and edible material composition and extract for assisting in regulating blood sugar, and preparation method and application thereof |
| CN115364170A (en) * | 2022-10-20 | 2022-11-22 | 云南中医药大学 | Sugar metabolism regulator and preparation method and application thereof |
| CN115364170B (en) * | 2022-10-20 | 2023-01-24 | 云南中医药大学 | Sugar metabolism regulator and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102727586B (en) | Composition for preventing and treating diabetes | |
| CN101708295B (en) | Chinese medicinal preparation for treating diabetes and preparation methods thereof | |
| CN102727706A (en) | Composition for preventing and treating diabetes | |
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| CN102366595B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN104784505A (en) | Dendrobium officinale healthcare product with auxiliary blood glucose reducing function and preparation method thereof | |
| CN101647857B (en) | Chinese medicine composition for treating stein-leventhal syndrome and preparation method thereof | |
| CN100548342C (en) | Take night in Tibetan medicine for the treatment of diabetes and preparation method thereof | |
| CN118105451A (en) | Medicinal and edible composition for preventing and treating ulcerative colitis and application thereof | |
| CN103417846A (en) | Hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| CN102488830B (en) | Pharmaceutical composition for lowering blood sugar | |
| CN102631482B (en) | Chinese medicinal composition for preventing and treating diabetes and complications | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN102836354B (en) | Medicament for treating depression | |
| CN103463207B (en) | Prevent and treat the composition of diabetes | |
| CN100339119C (en) | Traditional Chinese medicine prepns. for treating diabete | |
| CN104689151A (en) | Traditional Chinese medicine composition for treating diabetes and use of composition | |
| CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
| CN1463734A (en) | A prepared Chinese medicine for treating diabetes mellitus and method for preparing same | |
| CN115779046B (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes | |
| CN103495014B (en) | Medicament for treating depression in psychiatric nursing | |
| CN102366540A (en) | Medicine for treating diabetes and its preparation method | |
| CN102366443B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN102000244B (en) | Traditional Chinese medicine preparation for treating diabetes mellitus | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121017 |